Can't afford it anymore? Here is every real option, in order

First, the reframe the situation deserves

Losing access for money reasons is the most common way people stop these medications, and it is the least discussed. The trials study people who choose to stop; the real world is full of people whose insurer chose for them, mid-loss, with two pens left in the fridge. If that is you: the medication was working, you did nothing wrong, and the problem you are solving this week is logistics, not character. Now the options, cheapest disruption first.

Option 1: the manufacturer direct-pay programs

Both manufacturers now sell directly to self-pay patients at a fraction of list price, and this is the single most useful fact on this page. As of fall 2026: LillyDirect offers Zepbound single-dose vials at roughly $299 to $449 per month by dose, and NovoCare offers Wegovy at roughly $149 to $349 per month. The catches: cash only (insurance cannot be billed), a telehealth or membership fee often rides along, vial handling replaces the familiar pen for some doses, and the prices and terms have changed several times, so treat these numbers as the neighborhood, not the contract. If your budget broke at $1,000, it may not be broken at $300, and that math is worth running before any of the harder options below.

Option 2: fight the denial

Insurance denials are frequently about paperwork, not policy. The same medication gets approved or denied depending on the diagnosis submitted, the comorbidities documented, and whether anyone bothered to appeal. Ask your prescriber's office to: file the prior authorization appeal (they have templates), document every qualifying comorbidity, and check whether a different diagnosis pathway fits your chart. Persistence has a real hit rate here, and the office staff know it.

Option 3: switch to whatever the formulary does cover

"We no longer cover Wegovy" often coexists with "Zepbound is tier 2." The molecules are not interchangeable, but both work, and a covered drug beats an unaffordable one every time. How the switch actually goes, including the head-to-head data and the dose restart question, is the switching guide's whole subject, and the comparison tool covers the full menu.

Option 4: the lower-dose conversation

Fewer milligrams can mean fewer dollars, and maintenance is not escalation: plenty of people hold their weight at doses below the top of the ladder. The honest version of this option runs through your prescriber, framed exactly as the money problem it is: "what is the lowest-cost regimen that still works for me." The microdosing chart maps the three versions of "less" with the evidence attached, and the dosage chart shows which rungs the labels treat as legitimate places to live. What this option is not: silently stretching doses and hoping. Unsupervised is the failure mode; supervised is a plan.

The option to skip: the gray market

The cheap compounded era ended in 2025 when the FDA declared the shortages resolved and the copies had to stop. What filled the vacuum is a gray market of "research use only" peptide vials sold without prescriptions, with no purity testing, no dosing assurance, and no one accountable when the vial is not what the label says. Whatever this page is, it is not going to walk you toward injecting an unverified substance to save money. The $149 program above exists; use that math instead.

Option 5: stopping, with the plan the trials never gave people

Sometimes every door above is closed, and the honest next move is a planned exit. What makes cost-forced stopping uniquely brutal is the suddenness: no taper conversation, just a last pen. If there is any runway at all, the weaning guide covers the step-down conversation, and even two or three step-down months change what the first drug-free weeks feel like. Either way, the sequence is knowable: the washout calculator shows how long the medication keeps working after the last dose, and what happens when you stop walks the weeks after, including the window where the food noise comes back.